March 9th, 2013
ACC.13 Headquarters
CardioExchange Editors, Staff
CardioExchange is dedicated to bringing you the latest from ACC.13. Check out our coverage below ─ and some of the great debates these posts have sparked ─ then tell us what you think!
News:
- Following an Embargo Break PREVAIL Trial Won’t be Presented at ACC
- HPS2-THRIVE: A ‘Disappointing But Clear’ Result
- Cangrelor During PCI May Reduce Ischemic Events
- Fibrinolysis May Benefit Late-Arriving STEMI Patients
- Eplerenone May Prevent Heart Failure in Acute STEMI Patients
- Another Negative Trial of Darbepoetin Alfa
- Was Atherosclerosis the Real Curse of the Mummy?
- Two Trials Explore On-Pump Versus Off-Pump Bypass Surgery
Analysis:
Follow our Fellows:
- The Real World Intrudes on the Start of the Meeting
- A Fellow Reflects on the Program and on her Progress from Observer to Educator
- Data Sources for Young Investigators
- New Approaches to LDL Lowering
- Great Venue, Great Sessions, but Disappointments Too
- Thinking About What Comes After Fellowship
- The Real Question About Reducing Hospital Readmissions
- You Are My Sunshine
- Learning to Network
NEJM Journal Watch — Recent Cardiology Articles- More Data on Lp(a): This Time on Recurrent ASCVD Risk
- New Life for a Failed Drug Class
- Support for Moderate-Intensity Statin plus Ezetimibe in Older Patients
- Can Electronic Provider Notification Improve Outcomes in Severe Aortic Stenosis?
- Do Patients with Histories of Takotsubo Syndrome Have Increased Long-Term Morbidity?